Uceris® (budesonide MMX®)
Mild-to-moderate ulcerative colitis
ApprovedCommercial
Key Facts
Indication
Mild-to-moderate ulcerative colitis
Phase
Approved
Status
Commercial
Company
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals is a publicly traded, revenue-generating biopharmaceutical company with a strategic focus on gastroenterology. Its core expertise lies in the MMX® multi-matrix system, a proprietary technology enabling targeted topical delivery of drugs to the colon. The company's strategy combines the commercialization of its approved products, like Uceris® and Methylene Blue MMX®, with the advancement of its clinical pipeline, including novel candidates for ulcerative colitis and Crohn's disease, while also engaging in strategic licensing and partnership agreements.
View full company profile